Reuters.com is your online source for the latest news stories and current events, ensuring our readers up to date with any breaking news developments ...

Pfizer Inc.'s experimental drug for cancer weight loss was shown to help patients regain weight in a mid-stage study, ...

As Eli Lilly and Novo Nordisk continue to dominate the lucrative weight-loss drug market, smaller competitors are gearing up ...

Pfizer said Thursday that it is back in the race to get an effective weight-loss pill to market. The company’s announcement, ...

Data from an early stage clinical trial suggests Novo Nordisk’s new weight loss pill amycretin could produce greater and more ...

The weight-loss market is heating up as a number of companies are looking for a way to upend the dominance of market leaders Novo Nordisk ( NVO) and Eli Lilly ( LLY) by introducing GLP-1 pills.

Cancer patients with wasting syndrome have gained weight after taking Pfizer’s anti-GDF-15 antibody in a midphase study, ...

On the heels of Terns’ positive Phase I results that analysts compared with Lilly’s and Pfizer’s weight loss pills in ...

The race is on to develop the first daily weight-loss pill that would be both cheaper and less invasive than the current ...

The novel drugs work by mimicking the gut hormone GLP-1, which lowers blood sugar and limits the appetite. Treatments such as ...

The ultimate battle may be over which drugmaker can deliver the best, most effective weight loss pill. Earlier this month, Pfizer said that it would be moving ahead with clinical trials for a once ...

The release of early-stage data on three oral weight loss drug candidates hints at which companies have the strongest hand, ...